



Monday, January 22, 2007

Dear Fellow Shareholders of Nutra Pharma,

As we start off the New Year, I would like to take a moment to share with you some of our key accomplishments in the 4th quarter of 2006. These past few months were very important for Nutra Pharma - Not only did we receive approval to begin our Phase IIb/IIIa human clinical trial for the treatment of Adrenomyeloneuropathy (AMN), but we also made significant advancements with our Designer Diagnostics Tuberculosis test kits.

You might recall that in October, we teamed with St. Louis' World Aquarium to support conservation and snake education by adopting their 2-headed snake. We received some very positive press for this sponsorship. Articles appeared in a number of magazines and newspapers, including a nice article by the Associated Press. In addition, Nutra Pharma was featured on television news stations around the country. We felt this sponsorship fit well with our Company, given ReceptoPharm's research using modified cobra venom and cobratoxin.

We have all been anticipating the launch of the Designer Diagnostics Tuberculosis test kits. As I am sure most of you read in one of our latest press releases, Designer Diagnostics received positive results from its in-vitro analysis that was completed in December. This is a significant milestone for Designer Diagnostics and allows us to begin our human clinical trials. We anticipate that these trials will be completed within the first quarter of 2007. We expect to begin sales and marketing of these test kits shortly after the successful completion of these trials.

If you haven't already, be sure to sign up for our e-mail alerts online to ensure that you receive the latest news and announcements as they become available. We hope to bring you some very important news this quarter as we continue to build the Company and begin our human clinical trials. As always, if you have any questions or would like additional information, please contact our investor relations hotline toll-free at (877) 895-5647.

Sincerely yours,

Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation
Ticker Symbol: OTC: NPHC